Metastasis From Malignant Tumor Of Prostate — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for metastasis from malignant tumor of prostate. 42 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
42
Active US patents
65/100
Avg vulnerability
$7.1B
Annual revenue covered

Originators in Metastasis From Malignant Tumor Of Prostate

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson 28 patents Astellas Pharma 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating metastasis from malignant tumor of prostate. Each bar = one year. Y-axis scaled to peak year (15 patents).

3
26
9
27
2
30
15
33
2
35
3
37
2
38
4
40
2
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Erleada
apalutamide
 Johnson & Johnson 28 67 $2.6B 2027-03-27
Xtandi
enzalutamide
 Astellas Pharma 14 62 $4.5B 2026-08-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8802689 Erleada method of use 88 2027-03-27
8183274 Xtandi method of use 85 2026-08-24
8183274 Xtandi method of use 80 2026-08-24
8183274 Xtandi method of use 80 2026-08-24
8802689 Erleada method of use 80 2027-03-27
8445507 Erleada method of use 76 2030-09-15
12502357 Xtandi method of use 75 2033-09-11
12502357 Xtandi method of use 75 2033-09-11
12447128 Xtandi method of use 75 2033-09-11
RE50642 Erleada method of use 75 2033-09-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7709517 Xtandi composition of matter 17 2027-08-13
7709517 Xtandi composition of matter 17 2027-08-13
7709517 Xtandi composition of matter 22 2027-08-13
9388159 Erleada composition of matter 22 2027-03-27
9388159 Erleada composition of matter 30 2027-03-27
11839689 Xtandi formulation 50 2033-09-11
11839689 Xtandi formulation 50 2033-09-11
12303493 Erleada formulation 55 2035-12-03
12303493 Erleada formulation 55 2035-12-03
9987261 Erleada formulation 60 2027-03-27

Related